# US 2014/0154211 A1 · 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0154211 A1
- Document ID: US20140154211A1
- Status: Published application
- Kind: A1
- Application number: 14/111,687
- Filed: 2012-04-11
- Published: 2014-06-05
- Earliest claimed: 2011-04-13
- Assignees: Merck Sharp & Dohme Corp.
- Inventors: Vinay Girijavallabhan; F. George Njoroge; Stephane Bogen; Vishal Verma; Frank Bennett; Angela Kereles; Ashok Arasappan; Dmitri Pissarnitski; Qun Dang; Ian Davies; David B. Olsen; Andrew Stamford; Joseph P. Vacca
- Web page: https://patentgrep.com/patent/US20140154211A1

## CPC

- A61K 31/7072: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A01N 47/36: containing the group >N—CO—N< directly attached to at least one heterocyclic ring; Thio analogues thereof
- A61K 31/7042: Compounds having saccharide radicals and heterocyclic rings
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/14: for RNA viruses
- C07H 17/02: Heterocyclic radicals containing only nitrogen as ring hetero atoms
- C07H 19/10: with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H 19/11: containing cyclic phosphate
- C07H 19/207: the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
- C07H 19/213: containing cyclic phosphate
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

The present invention relates to 2′-Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, X, R1, R2 and R3 are as defined herein. The present invention also relates to compositions comprising at least one 2′-Substituted Nucleoside Derivative, and methods of using the 2′-Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.

## Claims

### Claim 1

A compound having the structure:
or a pharmaceutically acceptable salt thereof,
wherein:
X is O, S Or CH2;
A is C2-C6 alkenyl, C2-C6 alkynyl, 5- or 6-membered monocyclic heteroaryl, Cl, —N(R20)2, —S—(C1-C6 alkyl), —S(O)—(C1-C6 alkyl), —S(O)2—(C1-C6 alkyl), —(C1-C6 alkylene)-OH, —(C1-C6 alkylene)-N(R20)2, —NHSO2—(C1-C6 alkyl), —NHC(O)N(R20)2, —NHOH, —C(O)OR20, —C(O)N(R20)2, —NHC(O)R20 or —NHC(O)OR20, or group A and the —OR2 group of formula (I) can join to form —OC(O)—NH—;
B is a natural or non-natural purine or pyrimidine base, or B is selected from one of the following groups:
Y is N or —C(R19)—;
Z is N or —CH—;
R1 is H,
R2 is H, or R1 and R2 join to form a group having the formula:
R3 is C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C2-C6 alkenyl, C2-C6 alkynyl or C3-C7 cycloalkyl;
R4, R5, R7 and R8 are each independently H, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, halo, —OR20, —SR20 or —N(R20)2;
R6, R9, R10, R11 are each independently selected from H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, 4- to 7-membered heterocycloalkyl, 5- or 6-membered monocyclic heteroaryl, 9- or 10-membered bicyclic heteroaryl, halo, —OR20, —SR20, —S(O)R20, —S(O)2R20, —S(O)2N(R20)2, —NHC(O)OR20, —NHC(O)N(R20)2, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, —O—(C1-C6 haloalkyl), —CN, —NO2, —N(R20)2, —NH(C1-C6 alkylene)-(5- or 6-membered monocyclic heteroaryl), —NH(C1-C6 alkylene)-(9- or 10-membered bicyclic heteroaryl), —C(O)R20, —C(O)OR20, —C(O)N(R20)2 and —NHC(O)R20, wherein said C2-C6 alkenyl group and said C2-C6 alkynyl group can be optionally substituted a halo group;
R12 is H or —(C1-C6 alkylene)-T-R21;
R13 is H or —(C1-C6 alkylene)-T-R21, or R12 and R13 can join to form a C2-C4 alkylene group between the oxygen atoms that R12 and R13 are attached to, wherein said C2-C4 alkylene group is substituted with at least one C6-C10 aryl group;
R14 is H, C6-C10 aryl, 5- or 6-membered monocyclic heteroaryl or 9- or 10-membered bicyclic heteroaryl, wherein said C6-C10 aryl group, said 5- or 6-membered monocyclic heteroaryl group and said 9- or 10-membered bicyclic heteroaryl group can be optionally substituted with R22;
R15 is H, C1-C6 alkyl, C3-C7 cycloalkyl, phenyl or benzyl, wherein said C1-C6 alkyl can be optionally substituted with a group selected from halo, —OR20, —SR20, guanidino, —N(R20)2, —C(O)OR20, —C(O)N(R20)2, —NHC(O)R20, 5- or 6-membered monocyclic heteroaryl and 9- or 10-membered bicyclic heteroaryl, and wherein said phenyl group and said benzyl group can be optionally substituted with up to 2 groups, each independently selected from C1-C6 alkyl, halo and —OR20;
R16 is H, C1-C6 alkyl, C3-C7 cycloalkyl, phenyl or benzyl, wherein said C1-C6 alkyl can be optionally substituted with a group selected from halo, —OR20, —SR20, guanidino, —N(R20)2, —C(O)OR20, —C(O)N(R20)2, —NHC(O)R20, 5- or 6-membered monocyclic heteroaryl and 9- or 10-membered bicyclic heteroaryl, and wherein said phenyl group and said benzyl group can be optionally substituted with up to 2 groups, each independently selected from C1-C6 alkyl, halo and —OR20;
R17 is H, C1-C20 alkyl, C2-C20 alkenyl, —(C1-C3 alkylene)m-C3-C7 cycloalkyl, —(C1-C3 alkylene)m-C6-C10 aryl or adamantyl, wherein said C1-C20 alkyl group, said C2-C20 alkenyl group, said C6-C10 aryl group and said adamantyl group can be optionally substituted with up to three groups, each independently selected from halo, —OR20, —C(O)OR20, CN, NO2, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C3-C7 cycloalkyl, C6-C10 aryl, 5- or 6-membered monocyclic heteroaryl, 9- or 10-membered bicyclic heteroaryl, —N(R20)2, —C(O)N(R20)2—SR20, —S(O)R20, —S(O)2R20, —S(O)2N(R20)2, —NHC(O)R20, —NHC(O)OR20 and —NHC(O)N(R20)2 and;
R18 is H, C1-C6 alkyl, C3-C7 cycloalkyl, —(C1-C3 alkylene)m-C6-C10 aryl, 5- or 6-membered monocyclic heteroaryl, 9- or 10-membered bicyclic heteroaryl or:
wherein said C6-C10 aryl group, said 5- or 6-membered monocyclic heteroaryl group and said 9- or 10-membered bicyclic heteroaryl group can be optionally substituted with up to five groups, each independently selected from C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo, —OR20, —SR20, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, —O—(C1-C6 haloalkyl), —CN, —NO2, —N(R20)2, —C(O)OR20, —C(O)N(R20)2 and —NHC(O)R20;
R19 is H, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, halo, —OR20, —SR20, N(R20)2, C3-C7 cycloalkyl, C6-C10 aryl, 5- or 6-membered monocyclic heteroaryl or 9- or 10-membered bicyclic heteroaryl;
each occurrence of R20 is independently H, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, —(C1-C3 alkylene)m-(C3-C7 cycloalkyl), —(C1-C3 alkylene)m-(C6-C10 aryl), —(C1-C3 alkylene)m-(4 to 7-membered heterocycloalkyl), —(C1-C3 alkylene)m-(5- or 6-membered monocyclic heteroaryl) or —(C1-C3 alkylene)m-(9- or 10-membered bicyclic heteroaryl), wherein said C3-C7 cycloalkyl group, said C6-C10 aryl group, said 4 to 7-membered heterocycloalkyl group, said -(5- or 6-membered monocyclic heteroaryl group or said 9- or 10-membered bicyclic heteroaryl group can be optionally substituted with R26;
each occurrence of R21 is independently H, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, C3-C7 cycloalkenyl, 5- or 6-membered monocyclic heteroaryl, 9- or 10-membered bicyclic heteroaryl, —OR20, —O—(C1-C6 haloalkyl) or —N(R20)2, wherein said C2-C6 alkenyl group, said C2-C6 alkynyl group, said C3-C7 cycloalkyl group, said C3-C7 cycloalkenyl group, said C6-C10 aryl group, said 5- or 6-membered monocyclic heteroaryl group and said 9- or 10-membered bicyclic heteroaryl group can be optionally substituted with up to five groups, each independently selected from C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo, —OR20, —SR20, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, —O—(C1-C6 haloalkyl), —CN, —NO2, —N(R20)2, —C(O)R20, —C(O)OR20, —C(O)N(R20)2 and —NHC(O)R20;
R22 K represents from one to five substituent groups, each independently selected from C1-C6 alkyl, halo, —OR20, —SR20, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, —O—(C1-C6 haloalkyl), —CN, —NO2, —N(R20)2, —C(O)OR20, —C(O)N(R20)2 and —NHC(O)R20, or any two R22 groups on adjacent ring carbon atoms can combine to form —O—R23—O—;
R23 is —[C(R24)2]n—;
each occurrence of R24 is independently H or C1-C6 alkyl;
each occurrence of R25 is independently H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, —(C1-C3 alkylene)m-(C6-C10 aryl), 4 to 7-membered heterocycloalkyl, 5- or 6-membered monocyclic heteroaryl or 9- or 10-membered bicyclic heteroaryl, wherein said C1-C6 alkyl group, said C2-C6 alkenyl group, said C2-C6 alkynyl group, said C3-C7 cycloalkyl group, said C6-C10 aryl group, said 4 to 7-membered heterocycloalkyl group, said -(5- or 6-membered monocyclic heteroaryl group or said 9- or 10-membered bicyclic heteroaryl group can be optionally substituted with R26; or two R25 groups, together with the common nitrogen atom to which they are attached, join to form a 4- to 7-membered heterocycloalkyl group;
R26 represents from one to five substituent groups, each independently selected from C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo, —OR27, —SR27, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, —O—(C1-C6 haloalkyl), —CN, —NO2, —N(R27)2, —C(O)OR27, —C(O)N(R27)2 and —NHC(O)R27;
each occurrence of R27 is independently H, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, —(C1-C3 alkylene)m-(C3-C7 cycloalkyl), —(C1-C3 alkylene)m-(C1-6—C1-10 aryl), —(C1-C3 alkylene)m-(4 to 7-membered heterocycloalkyl), —(C1-C3 alkylene)m-(5- or 6-membered monocyclic heteroaryl) or —(C1-C3 alkylene)m-(9- or 10-membered bicyclic heteroaryl);
R28 is H, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, C3-C7 cycloalkenyl, 5- or 6-membered monocyclic heteroaryl, 9- or 10-membered bicyclic heteroaryl, —OR20, —O—(C1-C6 haloalkyl) or —N(R20)2, wherein said C2-C6 alkenyl group, said C2-C6 alkynyl group, said C3-C7 cycloalkyl group, said C3-C7 cycloalkenyl group, said C6-C10 aryl group, said 5- or 6-membered monocyclic heteroaryl group and said 9- or 10-membered bicyclic heteroaryl group can be optionally substituted with up to five groups, each independently selected from C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo, —OR20, —SR20, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, —O—(C1-C6 haloalkyl), —CN, —NO2, —N(R20)2, —C(O)R20, —C(O)OR20, —C(O)N(R20)2 and —NHC(O)R20;
each occurrence of R29 is independently H, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, —(C1-C3 alkylene)m-(C3-C7 cycloalkyl), —(C1-C3 alkylene)m-(C6-C10 aryl), —(C1-C3 alkylene)m-(4 to 7-membered heterocycloalkyl), —(C1-C3 alkylene)m-(5- or 6-membered monocyclic heteroaryl) or —(C1-C3 alkylene)m-(9- or 10-membered bicyclic heteroaryl), wherein said C3-C7 cycloalkyl group, said C6-C10 aryl group, said 4 to 7-membered heterocycloalkyl group, said -(5- or 6-membered monocyclic heteroaryl group or said 9- or 10-membered bicyclic heteroaryl group can be optionally substituted with R26;
each occurrence of T is independently —S—, —O—, —SC(O)—, —SC(S)—, —OC(O)— and —OC(S)—;
each occurrence of m is independently 0 or 1; and
each occurrence of n is independently 1 or 2.

### Claim 2 (depends on 1)

The compound of claim 1, wherein X is O.

### Claim 3 (depends on 1, 2)

The compound of claim 1 or 2, wherein R3 is methyl.

### Claim 4 (depends on 1)

The compound of claim 1 having the formula:
or a pharmaceutically acceptable salt thereof,
wherein:
A is 5- or 6-membered monocyclic heteroaryl, C2-C6 alkynyl, —CH2NH2, —N(R20)2, —S—(C1-C6 alkyl), —S(O)2—(C1-C6 alkyl), —NHC(O)N(R20)2, —C(O)N(R20)2, —NHC(O)R20 or group A and the —OR2 group of formula (I) can join to form —OC(O)—NH—;
B is:
R1 is H or:
R2 is H, or R1 and R2 join to form a group having the formula:
R6 and R11 are each independently —N(R20)2;
R9 is —OH or —O—(C1-C6 alkyl);
R14 is C6-C10 aryl;
R15 and R16 are each independently H or C1-C6 alkyl;
R17 and R18 are each independently C1-C6 alkyl; and
each occurrence of R20 is independently H or —C(O)—(C1-C6 alkyl).

### Claim 5 (depends on 1)

The compound of claim 1 having the formula:
or a pharmaceutically acceptable salt thereof,
wherein:
A is 5- or 6-membered monocyclic heteroaryl, C2-C6 alkynyl, —CH2NH2, —N(R20)2, —S—(C1-C6 alkyl), —S(O)2—(C1-C6 alkyl), —NHC(O)N(R20)2, —C(O)N(R20)2, —NHC(O)R20 or group A and the —OR2 group of formula (I) can join to form —OC(O)—NH—;
B is:
R1 is:
R6 and R10 are each independently —N(R20)2;
R9 is —OH or —O—(C1-C6 alkyl); and
each occurrence of R20 is independently H or —C(O)—(C1-C6 alkyl).

### Claim 6 (depends on 1, 2, 3, 4)

The compound of any of claims 1-4, wherein A is —NH2.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The compound of any one of claims 1-6, wherein B is:
R6 is —NH2 or —NHC(O)CH3; R9 is —OH or —O—(C1-C6 alkyl); and R10 is —NH2.

### Claim 8 (depends on 1)

The compound of claim 1 having the formula:
or a pharmaceutically acceptable salt thereof,
wherein:
A is C2-C6 alkynyl or —NH2;
B is:
R1 is:
R9 is —OH or —O—(C1-C6 alkyl);
R14 is 1 phenyl, which can be optionally substituted with up to 2 halo groups, which can be the same or different; and
R17 is C1-C6 alkyl.

### Claim 9 (depends on 1, 2, 3, 4, 6, 7, 8)

The compound of any one of claim 1-4 or 6-8, wherein R14 is phenyl.

### Claim 10 (depends on 1, 2, 3, 4, 6, 7, 8, 9)

The compound of any one of claim 1-4 or 6-9, wherein R17 is ethyl or isopropyl.

### Claim 11 (depends on 1)

The compound of claim 1 having the formula:
or a pharmaceutically acceptable salt thereof,
wherein:
A is C2-C6 alkynyl or —NH2;
B is:
and
R18 is aryl or C1-C6 alkyl.

### Claim 12 (depends on 11)

The compound of claim 11, wherein R18 is isopropyl.

### Claim 13 (depends on 1)

The compound of claim 1 having the formula:
or a pharmaceutically acceptable salt thereof,
wherein:
B is:
R1 is:
and
R9 is —OH or —O—(C1-C6 alkyl).

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The compound of any of claims 1-13, wherein B is

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The compound of any of claims 1-13, wherein B is

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The compound of any of claims 1-13, wherein B is

### Claim 17 (depends on 1)

The compound of claim 1, being any one of the compounds numbered 1-99 in the above specification, or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 1)

The compound of claim 1, having the structure:
or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A pharmaceutical composition comprising an effective amount of the compound of any of claims 1 to 18, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 20 (depends on 19)

The pharmaceutical composition according to claim 19, further comprising a second therapeutic agent selected from the group consisting of HCV antiviral agents, immunomodulators, and anti-infective agents.

### Claim 21 (depends on 19)

The pharmaceutical composition according to claim 19, further comprising a third therapeutic agent selected from the group consisting of HCV protease inhibitors, HCV NS5A inhibitors and HCV NS5B polymerase inhibitors.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The use of the compound according to any of claims 1 to 18, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for inhibiting HCV NS5A activity or for preventing and/or treating infection by HCV in a patient in need thereof.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

A method of treating a patient infected with HCV comprising the step of administering an amount of (i) the compound according to any of claims 1 to 18, or a pharmaceutically acceptable salt thereof, or (ii) the composition according to any of claims 19-21 effective to prevent and/or treat infection by HCV in said patient.

### Claim 24 (depends on 23)

The method according to claim 23, further comprising the step of administering pegylated-interferon alpha and an HCV protease inhibitor to said patient.

### Claim 25 (depends on 23, 24)

The method according to claim 23 or 24, further comprising the step of administering ribavirin to said patient.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The use of the compound according to any of claims 1 to 18, or a pharmaceutically acceptable salt thereof, in a pharmaceutical composition for inhibiting HCV NS5A activity or for preventing and/or treating infection by HCV in a patient in need thereof.
